Skip to main content
OpenTrials
Completed

NCT Number: NCT03417505

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Davis, Sacramento, California, United States

Loading trial locations.

About this study

Dry eye (DE) is a common complaint of millions of people worldwide with a significant impact on quality of life. For decades, this condition has presented a challenge to eye care professionals as conventional therapies are often ineffective. Recently, scleral lenses have demonstrated to be a promising therapeutic and vision rehabilitative option for dry eye sufferers. Nonetheless, despite the benefits of scleral lenses for dry eye patients, inadequate wettability of scleral lenses with subsequent diminished comfort and visual clarity remains a concern for scleral lens wearers with dry eye.

Tangible Hydra-PEG (Tangible Science LLC, Menlo Park, CA, USA) is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time, ultimately enhancing contact lens comfort. While studies have shown that Tangible Hydra-PEG technology can improve contact lens discomfort (CLD) in soft contact lens and gas permeable lens wearers, to our knowledge, no clinical research investigation has examined the benefits of this new coating on scleral lens wear in dry eye sufferers. As such, the aim of this study is to compare the CLD and DE symptoms of dry eye scleral lens wearers between Tangible Hydra-PEG treated scleral lens wear and untreated scleral lens wear. CLD and DE signs will also be assessed to corroborate our findings.

This will be the first randomized double masked cross-over study to examine CLD and DE symptoms of Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population. Tangible Hydra-PEG treated scleral lenses can potentially minimize CLD and DE symptoms, ultimately improving outcomes for patients coping with dry eye disease. This study will provide new information about this innovative technology and help practitioners envisage rehabilitative options which will best optimize the quality of life of this important patient population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Reduced tear film break up time (TBUT), a sign of dry eye disease and contact lens discomfort
  • Scleral lens wearer (at least 8 hours per day for at least 5 days per week and have had their habitual lenses no longer than 1 year). Scleral lenses wear will be defined as 15.00 mm to 19.00 mm inclusive.

Exclusion criteria

  • Disorders that affect sensitivity (herpetic disease, severe diabetes mellitus)
  • Anatomic variations of the conjunctiva that can impair proper scleral lens fitting
  • Pregnancy
  • Best corrected Snellen visual acuity worse than 20/30 in either eye
  • Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration, keratoconus) which may significantly impact visual function.

Treatment and study plan

Scleral lenses treated with Tangible Hydra-PEG

Device

Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.

Other names: Tangible Hydra-PEG is a hydrophilic PEG-based lens coating

Untreated scleral lenses

Device

Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.

Other names: control

Primary outcomes

  1. Ocular Surface Tear Breakup Time

    Time frame: 30 days

    Tear breakup time of the ocular surface after wearing lenses

  2. Corneal Fluorescein Staining

    Time frame: 30 days

    Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses

  3. Ocular Surface Disease Index (OSDI) Questionnaire

    Time frame: 30 days

    Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).

  4. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)

    Time frame: 30 days

    Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.

Secondary outcomes

  1. Tear Breakup Time Over the Surface of the Scleral Lens

    Time frame: 30 days

    Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens

  2. Lid Wiper Epitheliopathy

    Time frame: 30 days

    Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.

  3. Contact Lens-related Papillary Conjunctivitis

    Time frame: 30 days

    Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis [0 (normal) to 4 (severe)] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.

  4. Temporal Conjunctival Lissamine Green Staining

    Time frame: 30 days

    Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).

  5. Nasal Conjunctival Lissamine Green Staining

    Time frame: 30 days

    Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).

Sponsors and collaborators

Lead sponsor

Tangible Science

Industry

Collaborators

  • Illinois College of Optometry
  • Nova Southeastern University
  • University of California, Davis

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jan 31, 2018
Registry last updated
Jan 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.